• News
    • Latest news
    • News search
    • Health
    • Finance
    • Food
    • Career news
    • Content series
    • Focus areas
    • Try Devex Pro
  • Jobs
    • Job search
    • Post a job
    • Employer search
    • CV Writing
    • Upcoming career events
    • Try Career Account
  • Funding
    • Funding search
    • Funding news
  • Talent
    • Candidate search
    • Devex Talent Solutions
  • Events
    • Upcoming and past events
    • Partner on an event
  • Post a job
  • About
      • About us
      • Membership
      • Newsletters
      • Advertising partnerships
      • Devex Talent Solutions
      • Contact us
Join DevexSign in
Join DevexSign in

News

  • Latest news
  • News search
  • Health
  • Finance
  • Food
  • Career news
  • Content series
  • Focus areas
  • Try Devex Pro

Jobs

  • Job search
  • Post a job
  • Employer search
  • CV Writing
  • Upcoming career events
  • Try Career Account

Funding

  • Funding search
  • Funding news

Talent

  • Candidate search
  • Devex Talent Solutions

Events

  • Upcoming and past events
  • Partner on an event
Post a job

About

  • About us
  • Membership
  • Newsletters
  • Advertising partnerships
  • Devex Talent Solutions
  • Contact us
  • My Devex
  • Update my profile % complete
  • Account & privacy settings
  • My saved jobs
  • Manage newsletters
  • Support
  • Sign out
Latest newsNews searchHealthFinanceFoodCareer newsContent seriesFocus areasTry Devex Pro
    • News
    • Global health

    Drug prices soar after pharma giants GSK and Sanofi exit Nigeria

    Nigerians struggle to buy their prescribed medicines due to continuous price jumps caused by the country’s high inflation rate, weak naira, high import duties, and a deluge of exits by multinationals such as GSK and Sanofi.

    By Pelumi Salako // 04 April 2024

    Related Stories

    New partnerships bring price parity between lenacapavir and oral PrEP
    New partnerships bring price parity between lenacapavir and oral PrEP
    Ozempic generics are coming. But will low-income countries benefit?
    Ozempic generics are coming. But will low-income countries benefit?
    Will African nations lose their leverage in an ‘America First’ health plan?
    Will African nations lose their leverage in an ‘America First’ health plan?

    Last October, Idoma Prince visited a pharmacy in Nigeria’s capital city of Abuja to replace his old inhaler but he returned home empty-handed.

    The 24-year-old user interface designer was shocked after he was told the cost of a Ventolin inhaler, which he uses for his asthma, was now 8,500 Nigerian naira ($5.34). He returned home with the thoughts of the shocking price looming in his mind. Just a few months before, he had bought the same product for 3,500 naira ($2.46).

    “I wasn’t prepared for that [price] at all so I had to delay getting it till I had enough money on me. This January I went to get [it] again and I saw that the price had gone up to 10,000 naira ($7.02) for one inhaler,” he told Devex.

    This article is free to read - just register or sign in

    Access news, newsletters, events and more.

    Join usSign in

    More reading:

    ► The AU plans to pool resources to unify $50B pharma market (Pro)

    ► Big Pharma slammed for executive payouts that nearly match R&D budget

    ► African Development Bank sets up foundation to boost pharma sector

    • Global Health
    • Social/Inclusive Development
    • Trade & Policy
    • Private Sector
    • GSK
    • Sanofi
    • Nigeria
    Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).

    About the author

    • Pelumi Salako

      Pelumi Salako

      Pelumi Salako is a Nigerian journalist covering culture, technology, inclusive economies, and development. His works have appeared in Al Jazeera, The Guardian, the Thomson Reuters Foundation, NPR, Foreign Policy, and elsewhere. He holds a B.A. in History and International Studies from the University of Ilorin.

    Search for articles

    Related Stories

    Global healthRelated Stories - New partnerships bring price parity between lenacapavir and oral PrEP

    New partnerships bring price parity between lenacapavir and oral PrEP

    Global HealthRelated Stories - Ozempic generics are coming. But will low-income countries benefit?

    Ozempic generics are coming. But will low-income countries benefit?

    The Future of Global HealthRelated Stories - Will African nations lose their leverage in an ‘America First’ health plan?

    Will African nations lose their leverage in an ‘America First’ health plan?

    Most Read

    • 1
      The silent, growing CKD epidemic signals action is needed today
    • 2
      Innovation meets impact: Fighting malaria in a warming world
    • 3
      Why capital without knowledge-sharing won't solve the NCD crisis
    • 4
      Inside Amazon’s human rights journey
    • 5
      Building hope to bridge the surgical access gap
    • News
    • Jobs
    • Funding
    • Talent
    • Events

    Devex is the media platform for the global development community.

    A social enterprise, we connect and inform over 1.3 million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people. We invite you to join us.

    • About us
    • Membership
    • Newsletters
    • Advertising partnerships
    • Devex Talent Solutions
    • Post a job
    • Careers at Devex
    • Contact us
    © Copyright 2000 - 2026 Devex|User Agreement|Privacy Statement